FDA's Medical Countermeasure Program Among Senate Funding Priorities
Executive Summary
FDA should spend $19 million of an increase in non-user fee funding in fiscal 2012 on the agency’s medical countermeasures effort, the Senate Appropriations Committee recommends in the report that accompanies the Agriculture/FDA appropriations bill approved by the panel Sept 8.
You may also be interested in...
FDA’s Generic Drug Office Goes On Diet Before Swallowing User Fees
Congress sets $52.9 million floor for Office of Generic Drugs in FY 2012, less than in 2011, as part of $3.8 billion FDA funding package. Overall, FDA gets a $50 million boost, but sequestration looms. Appropriations conferees enter the user fee debate, asking how fast FDA approves drug applications.
Obama's Drug Shortage Efforts Focus On Personnel, Persuasion
Executive order gives FDA no new authority, but will allow doubling of shortage staff and likely bolster issue awareness.
ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five
The finalized generic drug user fee agreement would clear most of the ANDA application backlog by the end of the first program cycle.